October 13, 2020 -- Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary net sales for the company during its third quarter.
For the period (end-September 30), Qiagen expects to report net sales of $481.3 million, up 26% at both actual and constant exchange rates from the $382.7 million produced in the third quarter of 2019. Non-COVID-19 testing products declined at only a mid-single-digit rate compared with the same period a year ago.
Qiagen said that preliminary adjusted earnings per share (EPS) are approximately $0.58 at constant exchange rates, up from adjusted EPS of $0.36 in the third quarter of 2019. Full results will be reported on November 4.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current